PROCEE D - HerniaSolutions

Ventral Patch
Partially Absorbable Mesh Device
RMC 8550905
Status 7/08
Made in Germany
PROCEED* Ventral Patch
Partially Absorbable Mesh Device
PROCEED* Ventral Patch (PVP) is a sterile, self-expanding, partially absorbable, flexible laminate mesh device
designed for the repair of hernias and other fascial deficiencies such as those caused by trocar use. The mesh patch
is comprised of multiple layers of absorbable and nonabsorbable materials, laminated together with an absorbable
polydioxanone polymer and is available in different sizes. Full details are provided in the catalogue.
Figure 1
See Figure 1
The bottom layer of the patch, facing underlying tissue and organ surfaces is comprised of an oxidized regenerated
cellulose (ORC) fabric bonded to PROLENE* Soft Mesh, a nonabsorbable, macroporous polypropylene mesh. The
polypropylene mesh side of the product allows for tissue ingrowth. The ORC side of the patch provides a
bioresorbable layer that physically separates the polypropylene mesh from underlying tissue and organ surfaces
while minimizing tissue attachment to the polypropylene mesh during the critical wound healing period. The
polypropylene mesh layer is encapsulated with layers of PDS* film.
The parietal side of the patch contains a polydioxanone polymer reinforcement film and positioning ring, which
provide memory to the patch. These patch reinforcements offer stability to help the clinician achieve proper
placement. VICRYL* Mesh is placed on top of the polydioxanone polymer reinforcement film to facilitate placement
of the mesh. The VICRYL Mesh layer is encapsulated with layers of PDS film. Anchoring straps of the patch are
designed to facilitate placement and fixation of the mesh device. An ETHIBOND* polyester suture is attached to each
anchoring strap enabling tension to be placed on the patch prior to fixation. After the patch has been fixated, the
sutures should be removed and discarded.
The ORC component is an absorbable off-white knitted fabric prepared by the controlled oxidation of regenerated
cellulose. The ORC layer is absorbed from the site of implantation within four (4) weeks. Absorption rate depends
upon several factors including the amount used and implantation site.
The PROLENE Soft Mesh components are constructed of knitted filaments of extruded polypropylene, identical in
composition to that used in PROLENE* Polypropylene Suture, Nonabsorbable Surgical Suture, U.S.P. (ETHICON, Inc.).
This material, when used as a suture, has been reported to be non-reactive and to retain its strength indefinitely in
clinical use. The PROLENE Soft Mesh affords excellent strength, durability and surgical adaptability, with a porous
structure to enable mesh incorporation into surrounding tissues.
The polydioxanone components are made from poly (p-dioxanone) polymer that is identical to the polymer used in
PDS* II Polydioxanone Suture, Synthetic Absorbable Suture, U.S.P. (ETHICON, Inc.). The polydioxanone polymer has
been found to be nonantigenic, nonpyrogenic, and to elicit only a mild tissue reaction during absorption. The
polydioxanone component is essentially absorbed within six (6) months.
The VICRYL Mesh component is prepared from polyglactin 910, a synthetic absorbable copolymer of glycolide and
lactide, derived respectively from glycolic acid and lactic acids. Polyglactin 910 polymer is identical to the polymer
used in VICRYL* Polyglactin 910 Synthetic Absorbable Suture, U.S.P. (ETHICON, Inc.). The polyglactin 910 polymer has
been found to be nonantigenic, nonpyrogenic, and to elicit only a mild tissue reaction during absorption. The
polyglactin 910 component is essentially absorbed within 56 to 70 days.
PROCEED Ventral Patch (PVP) is a laminate mesh device, whose PROLENE Soft Mesh component is knitted with
nonabsorbable fibers, used to reinforce or bridge traumatic or surgical wounds to provide extended support during
and following wound healing. The ORC is intended to physically separate the mesh from underlying tissue and organ
surfaces during the critical wound healing period, thereby reducing the severity and extent of tissue attachment to
the mesh.
An animal model shows that implantation of PVP elicits a mild inflammatory reaction that does not interfere with
integration of the mesh into adjacent tissue. The mesh remains soft and pliable, and normal wound healing is not
noticeably impaired.
The ORC, VICRYL Mesh, and polydioxanone components are essentially absorbed within six (6) months, whereas the
polypropylene material is not absorbed, nor is it subject to degradation or weakening by the action of tissue enzymes.
Minimal visceral tissue attachment has been demonstrated in an animal model that shows reduction in the extent
and severity of adhesions to the mesh.
PROCEED Ventral Patch (PVP) is intended for the repair of hernias or other abdominal fascial defects that require the
addition of a reinforcing or bridging material to obtain the desired surgical result.
PVP is also indicated for the repair of tissue deficiencies caused by trocar use.
None known.
Do not cut or reshape any portion of the PROCEED Ventral Patch (PVP), aside from the fixation appendages, as this
could impact effectiveness.
When this mesh is used in infants, children, pregnant women, or women planning pregnancies, the surgeon should
be aware that this product will not stretch significantly as the patient grows.
In animal studies, the PROCEED Mesh component (Polypropylene mesh encapsulated in PDS film with ORC) of
PROCEED Ventral Patch did not potentiate infections. It is recommended that the mesh not be used following planned
intraoperative or accidental opening of the gastrointestinal tract. If the mesh is used in a contaminated field,
contamination of the mesh may lead to infection that may require removal of the mesh.
PROCEED Ventral Patch is provided by ETHICON, Inc. as a single use, sterile product.
Do not resterilize. Do not use if packaging is opened or damaged. Discard opened unused products.
Ensure proper orientation; the ORC side must be oriented towards the viscera of the body.
Users should be familiar with surgical procedures and techniques involving nonabsorbable meshes before using
PROCEED Ventral Patch.
PROCEED Ventral Patch has an ORC component, which should not be used in the presence of uncontrolled and/or
active bleeding, as fibrinous exudates may increase the chance of adhesion formation.
Foreign body reactions may occur in some patients.
CAUTION: Federal (U.S.A.) Law restricts this device to sale by or on the order of a physician.
When fixating mesh, use caution not to penetrate the bottom layer of the mesh to avoid penetrating underlying tissue
layers. Do not fixate to the umbilicus.
Selected mesh size should allow for adequate overlap of the fascial defect on all sides.
The safety and effectiveness of PROCEED Ventral Patch in combination with solutions other than saline (such as
peritoneal instillates, and/or medications) have not been studied. Do not soak or stretch the PROCEED Ventral
Care should be taken to avoid intraoperative damage to the device, specifically the ORC (uniformly off-white) side of
the patch, e.g. with sharp instruments or thermal devices.
Currently available animal data concerning the amount of implanted absorbable material supports the implantation
of up to five medium size devices per 60 kg (132.3lb) body weight during a timeframe of 8 months.
Potential adverse reactions are those typically associated with surgically implantable materials, including
potentiation of procedure-related infection, inflammation, adhesion formation, seroma formation, hematomas, fistula
formation, and extrusion.
Correct surface orientation is critical for PROCEED Ventral Patch to function as intended. The VICRYL Mesh side (side
with straps) should be placed adjacent to those tissues where tissue ingrowth is desired. The ORC side (uniformly
off-white) should be placed adjacent to those tissues where minimal tissue attachment is desired (e.g. visceral
Uncontrolled and/or active bleeding should be controlled prior to placement of PROCEED Ventral Patch.
Hernia Repair Technique:
Just prior to insertion, dip mesh patch in saline for ease of use and to avoid attachment of tissue during insertion.
Fold the mesh patch into a semi-circle with the ORC side facing outward (straps folded in) for insertion into the defect
(See Fig. 2).
Figure 2
During insertion, secure suture loops with a clamp or fingers. When using a mesh clamp, be certain to avoid kinking
the mesh. Be sure to refold as previously described if re-insertion is needed. Once the mesh patch has been inserted
into the defect, manipulate the suture loops to facilitate proper positioning of the patch. Pulling up on the suture loops
allows the mesh patch to flatten itself against the abdominal wall.
Pull the device with sufficient tension to assure tight seating against the abdominal wall as demonstrated in
Figure 3.
Figure 3
It is important to manually ensure that no tissue is trapped between the device and the abdominal wall. Secure the
patch to the margins of the defect through the mesh straps to anterior fascia (Figure 4). Excess length of the straps
should be cut off and discarded. The incision should then be closed.
Figure 4
It is recommended that non-absorbable sutures be used to fixate the patch. Alternative means of fixation (i.e. tissue
adhesives, staples, tackers) have not been evaluated.
Store at 25°C or less and away from moisture. Avoid prolonged exposures to elevated temperatures.
PROCEED Ventral Patch (PVP) is available in single packages as sterile devices.
* = Trademark
See Instructions For Use
Method of Sterilization —
Use By – Year and Month
Do Not Reuse/Resterilize
Batch number
No Latex
25 °C or less
This page has been left blank intentionally
a Johnson & Johnson company
Somerville, NJ, U.S.A.
Made in Germany
Made by Johnson & Johnson MEDICAL GmbH
RMC 8550905
Status 7/08